Crystal financial tombstone, featuring a sandblasted map of the world, recognizing a licensing and commercialization agreement between X4 Pharmaceuticals and Norgine. The agreement centers onthe drug Mavorixafor, and encompasses Europe, New Zealand, and Australia. (25LNL023)